相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao et al.
CLINICAL CANCER RESEARCH (2012)
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
Areumnuri Kim et al.
LEUKEMIA RESEARCH (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Predictive Molecular Classifiers in Colorectal Cancer
Pierre Bohanes et al.
SEMINARS IN ONCOLOGY (2011)
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
Ker Yu et al.
CANCER BIOLOGY & THERAPY (2010)
PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
Ensar Halilovic et al.
CANCER RESEARCH (2010)
NVP-BEZ235 as a New Therapeutic Option for Sarcomas
Maria C. Manara et al.
CLINICAL CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE2 signalling in colorectal adenoma cells
A. Greenhough et al.
ONCOGENE (2010)
Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues
Sandrine Dufort et al.
ANALYTICAL BIOCHEMISTRY (2009)
Differentiation-Related Gene-1 Decreases Bim Stability by Proteasome-Mediated Degradation
Grazia Ambrosini et al.
CANCER RESEARCH (2009)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:: Implications for clinical imaging
Christian R. Schnell et al.
CANCER RESEARCH (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells
Maria T. Accioly et al.
CANCER RESEARCH (2008)
Resist or die FOXO transcription factors determine the cellular response to chemotherapy
Ana R. Gomes et al.
CELL CYCLE (2008)
Systemic treatment of colorectal cancer
Brian M. Wolpin et al.
GASTROENTEROLOGY (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells
Silvia Fernandez de Mattos et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Robert A. Cartlidge et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
PIK3CA mutation in colorectal cancer:: Relationship with genetic and epigenetic alterations
Katsuhiko Nosho et al.
NEOPLASIA (2008)
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
Shunsuke Kato et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas
Ji Miao et al.
APOPTOSIS (2007)
Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation
Ankie G. M. van Gorp et al.
CANCER RESEARCH (2006)
p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65
Beibei Cai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
The prevalence of PIK3CA mutations in gastric and colon cancer
S Velho et al.
EUROPEAN JOURNAL OF CANCER (2005)
Structure, regulation and function of PKB/AKT - a major therapeutic target
M Hanada et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2004)
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma
K Khaleghpour et al.
CARCINOGENESIS (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
KA West et al.
DRUG RESISTANCE UPDATES (2002)
Role of Akt/protein kinase B in metabolism
EL Whiteman et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action
K Hara et al.
CELL (2002)
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
RH Medema et al.
NATURE (2000)
分享论文
